Savant Capital’s United Therapeutics UTHR Stock Holding History

Savant Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.29M	Buy	7,918 +4,073	+106%	+$2.11M	0.01%	540
2026 Q2	$2.18M	Buy	3,845 +1,519	+65%	+$855K	0.01%	590
2026 Q1	$1.38M	Buy	2,326 +463	+25%	+$231K	0.01%	523
2025 Q4	$908K	Hold	1,863	–	–	0.01%	618
2025 Q3	$781K	Buy	+1,863	New	+$627K	﹤0.01%	645
2025 Q1	–	Sell	-10,205	Closed	-$3.6M	–	1417
2024 Q4	$3.6M	Buy	10,205 +266	+3%	+$97.8K	0.03%	291
2024 Q3	$3.56M	Buy	9,939 +199	+2%	+$67.2K	0.03%	286
2024 Q2	$3.1M	Sell	9,740 -122	-1%	-$32.3K	0.03%	279
2024 Q1	$2.27M	Buy	+9,862	New	+$2.23M	0.03%	329

Other funds holding UTHR

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return

Savant Capital's UTHR Position: Q3 2026 in Review

Savant Capital increased its United Therapeutics (UTHR) stake by 106% in Q3 2026, buying an estimated $2.11M and bringing the position to 7,918 shares worth $4.29M. The position accounts for 0.01% of the portfolio, ranked #540.

Savant Capital first reported a position in UTHR in Q1 2024 and has held it in 9 quarters since. 390 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

Savant Capital held 7,918 shares of United Therapeutics worth $4.29M as of Q3 2026.
Savant Capital bought 4,073 United Therapeutics shares in Q3 2026, an estimated $2.11M.
United Therapeutics made up 0.01% of Savant Capital's portfolio in Q3 2026, its #540 holding.
Savant Capital first reported a position in United Therapeutics in Q1 2024 and has held it in 9 quarters since.
390 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Savant Capital's 13F filing for Q3 2026, filed 6 Nov 2026.